Healthcare / Proton Pump Inhibitor Market - Global Growth, Trends And Forecast (2022 - 2027) By Types, By Application, By Regions And By Key Players: AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eli Lilly
Proton Pump Inhibitor Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eli Lilly
The Proton Pump Inhibitor market is estimated to grow at a CAGR of 4.9% over the forecast period, from USD 2,750 million in 2021 to USD 3,585 million in 2027.
Proton Pump Inhibitor Market Overview
Proton pump inhibitors are a class of drugs that primarily reduce stomach acid production. Stomach acid is a chemical that aids digestion, but too much of it causes inflammation and irritation of the esophagus, resulting in heartburn, ulcers in the stomach, and the first section of the small intestine, all of which have an impact on market growth. It also helps with a variety of other stomach issues, particularly in cases like gastroesophageal reflux disease, in which stomach acid often leaks into the esophagus. When contrasted to H2 blockers, these Proton pump inhibitors are frequently used. These medications are available in the form of pills and capsules that the patient takes orally. Furthermore, this aids in the development of a microscopic clinical ailment known as colitis, which is fueling market expansion. Furthermore, by focusing on limiting acid secretion, the proton pump is directly responsible for the secretion of H+ ions into the stomach lumen, which is commonly seen in gastric acid secretion.
Increase in the incidence of gastrointestinal illnesses, increase in the elderly population suffering from stomach problems, increase in gastroesophageal reflux disease, increase in the consumption of unhealthy diets, expanding lifestyle linked with sedentary work culture, increased cases of obesity, and others are some of the primary factors positively affecting the market's growth throughout the forecast period. According to recent studies, the prevalence of GRED in North America is estimated to be 18.1%–27.8%, in Europe it is expected to be 8.8%–25.9%, in East Asia it is considered to be 2.5%–7.8%, in the Middle East it is projected to be 8.7%–33.1%, in Australia it is 11.6%, and in South America it is 23.0%.
Industry News and Updates
10th Jul, 2020: Cadila Pharmaceuticals Ltd. Launches Esomeprazole tablets under brand name Esiloc™ in India for treatment of Hyperacidity --
Ahmedabad-based Cadila Pharmaceuticals Limited recently announced the launch of Esomeprazole tablets for treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc™. In an endeavor to improve the treatment options available for hyperacidity & drug induced Gastritis, Esiloc™ will be 50% more economical, thus making it a superior yet affordable choice. Esiloc™ will be made available in 20 mg and 40 mg tablets.
Proton Pump Inhibitor Market Latest Trends
Esomeprazole is one of the most profitable pharmaceuticals on the market, and it is typically used to treat the symptoms of GERD, heartburn, and other problems involving excessive stomach acids. Until March 28, 2014, when the FDA approved it as an over-the-counter medicine, the substance was sold as a prescription drug. The transition from a prescription-only drug to an over-the-counter (OTC) drug is expected to be a primary driving force behind the drug's sales in the near future.
What are the major Applications, Types and Regions for Proton Pump Inhibitor Market?
Market is segmented based on the type, applications, companies and regions.
By Type, it is segmented into
OTC (Over-the-counter) Drugs
Omeprazole
Lansoprazole
Esomeprazole
Other OTC Drugs
Prescription Drugs
Rabeprazole
Dexlansoprazole
Pantoprazole
Other Prescription Drugs
By Application, it is segmented into
Hospital
Laboratory
Others
Proton Pump Inhibitor Market Regional Analysis
North America is dominating the market owing to rise in GERD. Due to greater health awareness, increased per capita income expenditure, and improved healthcare infrastructure, Europe is the second-largest contributor to the market. The market in Asia Pacific is expected to develop significantly due to an increase in the elderly population, increased healthcare awareness, and increased government initiatives in the healthcare sector. Latin America and the Middle East are also expected to see significant market expansion.
North America
US
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Middle East & Africa
Latin America
The Proton Pump Inhibitor Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Proton Pump Inhibitor Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.
What is our Proton Pump Inhibitor Market report scope?
Report Attributes
Report Details
Forecast Period 2022 to 2027 CAGR
CAGR of 4.9% over the forecast period (2022-2027)
By Type
OTC (Over-the-counter) Drugs
Omeprazole
Lansoprazole
Esomeprazole
Other OTC Drugs
Prescription Drugs
Rabeprazole
Dexlansoprazole
Pantoprazole
Other Prescription Drugs
By Application
Hospital
Laboratory
Others
By Companies
AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eli Lilly and Company, Eisai Inc., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Santarus Inc., Takeda Pharmaceuticals, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Sanofi SA, Perrigo Company PLC, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., Redhill Pharma Limited, Cipla Limited, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Janssen
Regions Covered
North America
Europe
Asia-Pacific
Rest of the World
Countries Covered
US
Canada
Germany
France
UK
Italy
Spain
Rest of Europe
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
Latin America
Base Year
2022
Historical Year
2017 to 2021
Forecast Year
2022 to 2027
Number of Pages
108
Customization Available
Yes, the report can be customized as per your needs
Frequently Asked Questions
What is the growth rate of Proton Pump Inhibitor Market?
The Proton Pump Inhibitor Market is growing at a CAGR of 4.9% over the next 5 years.
Who are the key players in Proton Pump Inhibitor Market?
AstraZeneca, Bayer AG, Cadila Pharmaceuticals, Eli Lilly and Company, Eisai Inc., GlaxoSmithKline PLC, Johnson & Johnson, Pfizer Inc., Santarus Inc., Takeda Pharmaceuticals, Eisai Pharmaceuticals India Pvt. Ltd, Wyeth LLC, Sanofi SA, Perrigo Company PLC, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., Redhill Pharma Limited, Cipla Limited, Changzhou Siyao Pharmaceuticals, Yangzhou Pharmaceutical, Janssen
What are the significant types of Proton Pump Inhibitor Market?
Lansoprazole, Pantoprazole, Rabeprazole, Others
What are the major end-use applications of Proton Pump Inhibitor Market?
Hospital, Laboratory, Others
All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.
INTRODUCTION
MARKET DEFINATION
MARKET DYNAMICS
MARKET SEGMENTATION
REPORT TIMLINES
KEY STAKEHOLDERS
RESEARCH METHODOLOGY
DATA MINING
SECONDARY RESEARCH
PRIMARY RESEARCH
SUBJECT MATTER EXPERT ADVICE
QUALITY CHECK
FINAL REVIEW
DATA TRIANGULATION
BOTTOM-UP APPROACH
TOP-DOWN APPROACH
RESEARCH FLOW
EXECUTIVE SUMMARY
INTRODUCTION
GLOBAL PROTON PUMP INHIBITOR MARKET BY TYPE
GLOBAL PROTON PUMP INHIBITOR MARKET BY APPLICATION
MARKET DYNAMICS
DRIVERS
INCREASING DEMAND FOR PROTON PUMP INHIBITOR
RESTRAINTS
STRINGENT ENVIRONMENTAL REGUALTIONS
HIGH COST ON MATERIALS
OPPORTUNITIES
PROTON PUMP INHIBITOR GROWTH
APPLICATION OF PROTON PUMP INHIBITOR
IMPACT OF COVID 19
GLOBALPROTON PUMP INHIBITORMARKET, BY TYPE
INTRODUCTION
LANSOPRAZOLE
PANTOPRAZOLE
RABEPRAZOLE
OTHERS
GLOBAL PROTON PUMP INHIBITORMARKET, BY APPLICATION
SECONDARY RESEARCH Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.